How does ICER plan to determine whether health plans offer fair access to pharmaceuticals? I summarized their approach last year as outlined in their white paper titled “Cornerstones of ‘Fair’ Drug Coverage: Appropriate Cost-Sharing and Utilization Management Policies for Pharmaceuticals.” Last month, final protocol for their “Barriers to Fair Access Assessment“. While the approach follows their previous protocol and white paper, not all all the criteria in this white paper are being evaluated. Which criteria is ICER evaluating? I have summarized the criteria ICER plans to include and exclude in their “Fair Access” assessment below.